|1.||White, H: 1 article (08/2001)|
|2.||Weitz, J I: 1 article (08/2001)|
|3.||Peters, R J: 1 article (08/2001)|
|4.||Molhoek, P G: 1 article (08/2001)|
|5.||Gibson, M: 1 article (08/2001)|
|6.||Spickler, W: 1 article (08/2001)|
|7.||Anderson, H V: 1 article (08/2001)|
|8.||Hirsh, J: 1 article (08/2001)|
|9.||Weaver, W D: 1 article (08/2001)|
|10.||Théroux, P: 1 article (08/2001)|
08/01/2001 - "Major bleeding was observed in 13% and 28% at these vasoflux doses compared with 8% with UFH (P =.558 and.01, respectively). "
08/01/2001 - "However, there was an excess of bleeding in the patients randomized to vasoflux 8 or 16 mg/kg: 78% and 71%, compared with 53% for UFH (P =.004 and.043, respectively). "
08/01/2001 - "At doses that increase the risk of bleeding, the addition of vasoflux to streptokinase and aspirin did not lead to improved patency rates compared with UFH. "
08/01/2001 - "Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis)."
08/01/2001 - "We randomized 277 patients with acute myocardial infarction to standard intravenous unfractionated heparin (UFH) or intravenous vasoflux 1, 4, 8, or 16 mg/kg as a bolus followed by 1, 4, 8, or 16 mg/kg per hour infusion, on top of streptokinase and aspirin, until angiography at 90 minutes. "
08/01/2001 - "Vasoflux is a low-molecular-weight heparin derivative that inhibits factor IXa activation of factor X and catalyzes fibrin-bound thrombin inactivation by heparin cofactor II. We studied whether vasoflux improves the results of thrombolysis with streptokinase for acute myocardial infarction. "
|2.||Aspirin (Acetylsalicylic Acid)
|4.||Factor IXa (Coagulation Factor IXa)
|5.||Heparin Cofactor II
|7.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
|9.||Factor X (Stuart Factor)